CAS NumberATC CodePubChemDrugBankChemSpider IDUNIIKEGGChEBIChEMBL
Chemical Data
CHNOMolecular Weight
Metergotamine is a pharmaceutical drug belonging to the class of ergot alkaloids. It is primarily used in the treatment of migraine headaches and is known for its vasoconstrictive properties. Metergotamine is a derivative of ergotamine, which is a naturally occurring compound found in the ergot fungus.
Metergotamine works by constricting blood vessels in the brain, which helps to alleviate the symptoms of a migraine. It acts as an agonist at several serotonin receptors, particularly the 5-HT1B and 5-HT1D subtypes, which are involved in the regulation of vascular tone.
The primary mechanism of action of metergotamine is its ability to bind to and activate serotonin receptors in the cranial blood vessels. This leads to vasoconstriction, which reduces the dilation of blood vessels that is associated with migraine headaches. Additionally, metergotamine may inhibit the release of pro-inflammatory neuropeptides, further contributing to its therapeutic effects.
Metergotamine is indicated for the acute treatment of migraine attacks with or without aura. It is not intended for prophylactic therapy or for the management of chronic migraine.
Metergotamine is available in oral and intravenous formulations. The dosage must be carefully adjusted according to the patient's response and tolerance. It is important to follow the prescribed dosage regimen to minimize the risk of adverse effects.
Common side effects of metergotamine include nausea, vomiting, dizziness, and fatigue. More serious adverse effects can occur, such as hypertension, myocardial ischemia, and peripheral vasoconstriction. Due to these potential risks, metergotamine should be used with caution in patients with cardiovascular disease.
Metergotamine is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, and peripheral vascular disease. It is also contraindicated during pregnancy due to its potential to cause uterine contractions and fetal harm.
Metergotamine can interact with other medications, including beta-blockers, macrolide antibiotics, and protease inhibitors. These interactions can increase the risk of adverse effects and should be carefully managed by healthcare providers.
Metergotamine was developed as a semi-synthetic derivative of ergotamine to improve its pharmacokinetic properties and reduce side effects. It has been used in clinical practice since the mid-20th century and remains a valuable option for the acute management of migraines.
Ongoing research is focused on developing new formulations of metergotamine with improved efficacy and safety profiles. Studies are also exploring its potential use in other conditions characterized by vascular dysregulation.
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer. Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
